5 Key Takeaways

• 1

  MCO-010 was designed to restore vision in severe retinal disease by stimulating surviving bipolar cells after photoreceptor loss.

• 2

  The therapy fuses three light-sensitive proteins to broaden light responsiveness while preserving the kinetics needed for dynamic vision.

• 3

  Mohanty said an engineered AAV vector delivers the three-protein complex to bipolar cells, which remain abundant in patients with low vision.

• 4

  In a phase 1/2 trial, 7 of 8 patients improved by more than 3 lines of visual acuity, and color vision improvements were reported across 3 trials.

• 5

  Mohanty reported durable vision restoration for up to 4 years and described MCO-010 as a potential approach for inherited retinal diseases and geographic atrophy.